Franklin Resources Inc. raised its holdings in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 6.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,337,569 shares of the company’s stock after acquiring an additional 200,310 shares during the period. Franklin Resources Inc. owned about 6.74% of Karyopharm Therapeutics worth $32,041,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Teacher Retirement System of Texas bought a new position in Karyopharm Therapeutics during the fourth quarter valued at approximately $115,000. Voya Investment Management LLC grew its holdings in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Karyopharm Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after purchasing an additional 5,586 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Karyopharm Therapeutics by 33.6% in the second quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock worth $255,000 after purchasing an additional 7,099 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Karyopharm Therapeutics by 18.8% in the fourth quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after purchasing an additional 4,902 shares during the last quarter. Institutional investors and hedge funds own 62.60% of the company’s stock.
Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 9th. Robert W. Baird set a $22.00 target price on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald restated a “buy” rating and issued a $18.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, January 25th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $19.00 target price (up previously from $18.00) on shares of Karyopharm Therapeutics in a report on Friday, March 16th. Finally, ValuEngine upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating and ten have given a buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average target price of $19.60.
In related news, Director Mansoor Raza Mirza sold 2,500 shares of Karyopharm Therapeutics stock in a transaction on Monday, March 12th. The shares were sold at an average price of $17.01, for a total value of $42,525.00. Following the sale, the director now owns 2,500 shares in the company, valued at $42,525. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction on Monday, January 8th. The shares were sold at an average price of $10.08, for a total transaction of $100,800.00. Following the completion of the sale, the insider now owns 723,510 shares in the company, valued at approximately $7,292,980.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,000 shares of company stock worth $928,625. 14.71% of the stock is currently owned by company insiders.
Shares of KPTI stock opened at $15.66 on Wednesday. Karyopharm Therapeutics Inc has a fifty-two week low of $7.48 and a fifty-two week high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million during the quarter, compared to the consensus estimate of $2.26 million. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 89.62%. The business’s revenue was up 3163.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.65) EPS. equities analysts forecast that Karyopharm Therapeutics Inc will post -2.72 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Franklin Resources Inc. Acquires 200,310 Shares of Karyopharm Therapeutics Inc (KPTI)” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/21/franklin-resources-inc-acquires-200310-shares-of-karyopharm-therapeutics-inc-kpti.html.
Karyopharm Therapeutics Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.